Takeda Unveils Promising Long-Term Results for HYQVIA® in CIDP Patients at PNS Annual Meeting

June 19, 2024 Osaka, Japan & Cambridge, Mass., United States Takeda today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and efficacy of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant…